康柏西普玻璃体腔注射治疗湿性年龄相关性黄斑变性

摘要

目的：观察康柏西普玻璃体腔注射治疗湿性年龄相关性黄斑变性的临床疗效。　　方法：将确诊的60例湿性年龄相关性黄斑变性的患者,根据随机数字表法分为治疗组和对照组各30例。治疗组注射康柏西普0.05mL,对照组注射曲安奈德0.1mL。在治疗前及治疗后1d,1、3mo采用标准视力表对患者进行最佳矫正视力( BCVA)检查；用光学相干断层扫描仪( OCT)检测黄斑中心凹视网膜厚度。并观察患者治疗后1d,1、3 mo内出现的并发症情况,包括前房炎性反应、角膜水肿、高眼压等。　　结果：治疗组治疗后1d,1、3mo视力提高明显好于对照组(P<0.05)。治疗组治疗后1d,1、3mo的黄斑中心凹视网膜厚度明显低于对照组(P<0.05)。治疗组和对照组治疗后1d,1、3mo均未出现眼部严重并发症。　　结论：康柏西普玻璃体腔注射治疗湿性年龄相关性黄斑变性可以提高疗效。%AIM: To observe the clinical curative effect of conbercept intravitreal injection for the treatment of wet age-related macular degeneration. METHODS:Sixty patients with wet age related macular degeneration were randomly divided into treatment group 30 cases and control group 30 cases according to the random number table. The treatment group was injected with Conbercept 0. 05mL, the control group was injected with triamcinolone acetonide 0. 1mL. The best corrected visual acuity (BCVA) was performed before and after 1d, 1 and 3mo after treatment, and the thickness of macular was detected by optical coherence tomography ( OCT ) . The complications of patients were observed after 1d, 1 and 3mo, including inflammatory reaction, corneal edema, anterior chamber, high intraocular pressure, etc.RESULTS:In treatment group 1d, 1 and 3mo after treatment, eyesight was improved significantly better than the control group (P<0. 05), macular center concave retinal thickness was significantly lower than the control group (P<0. 05). Treatment group and control group 1d, 1 and 3mo after treatment did not appear serious eye complications. CONCLUSION:Intravitreal injection of Conbercept in the treatment of wet age-related macular degeneration can improve the curative effect.